The in vitro tumor killing capability from CAR-T, δ-TCRγδ-T, and γ-TCRγδ-T after tumor killing exhibited a similar pattern to the results obtained from T cells engineered with anti-PD-L1 scFv. This evidence concerns the gene CD274 and neoplasm.